malondialdehyde has been researched along with ezetimibe in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ciralik, H; Gümüşalan, Y; Kilinc, M; Ozbag, D; Toru, H; Yasim, A | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Carru, C; Deiana, L; Loriga, G; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Carru, C; Mangoni, AA; Sanna, M; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A | 1 |
| Abe, S; Hashimoto, R; Hasumi, H; Hirose, S; Inoue, T; Masuyama, T; Numao, T; Sakuma, M; Toyoda, S; Waku, R; Yazawa, H | 1 |
3 trial(s) available for malondialdehyde and ezetimibe
| Article | Year |
|---|---|
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy.
Topics: Aged; Allantoin; Azetidines; Drug Administration Schedule; Drug Combinations; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Kidney; Kidney Failure, Chronic; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Simvastatin; Sulfhydryl Compounds; Superoxides; Taurine; Uric Acid | 2012 |
Impact of cholesterol lowering treatment on plasma kynurenine and tryptophan concentrations in chronic kidney disease: relationship with oxidative stress improvement.
Topics: Aged; Allantoin; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Healthy Volunteers; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; NF-kappa B; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Taurine; Triglycerides; Tryptophan; Uric Acid | 2015 |
3 other study(ies) available for malondialdehyde and ezetimibe
| Article | Year |
|---|---|
Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Catalase; Cholesterol, Dietary; Ezetimibe; Glutathione Peroxidase; Heptanoic Acids; Lipid Metabolism; Lipid Peroxidation; Lipids; Malondialdehyde; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2010 |
Effect of cholesterol lowering treatment on plasma markers of endothelial dysfunction in chronic kidney disease.
Topics: Allantoin; Anticholesteremic Agents; Arginine; Biomarkers; Cholesterol; Endothelium; Ezetimibe; Female; Humans; Inflammation; Kynurenine; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Renal Insufficiency, Chronic; Simvastatin; Uric Acid | 2016 |
Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Oxidative Stress | 2019 |